Skip to main content

Table 1 Demographic and clinical characteristics at baseline of refractory chronic migraine patients treated with Erenumab

From: A prospective real-world analysis of erenumab in refractory chronic migraine

 Total number of patients
Sex, M/F27/135
Age (y), mean ± SD46 ± 14.3
CM duration (y), mean ± SD13 ± 11.9
Aura, N (%)53 (33%)
Medication overuse, N (%)87 (54%)
 Mean ± St. Error
Migraine days19.7 ± 0.7
Headache days23.4 ± 0.6
Headache free days3.7 ± 0.4
Abortive treatment intake days11.5 ± 0.7
HIT-6 score67.6 ± 0.4
Number of preventive treatments failed8.4 ± 3.6
BoNT/A non-responders148 (91.4%)
  1. BoNTA: onabotulinum toxinA, CM, chronic migraine; F, female; HIT-6, headache impact test-6; M, male; N, number; Y, years
\